The New Epidemiology of Primary Biliary Cirrhosis

Abstract

Primary biliary cirrhosis (PBC) is an autoimmune cholestatic liver disease. Susceptibility to PBC probably arises from a combination of genetic and environmental factors. The prevalence of PBC varies both on an international and a regional level. This can be explained, in part, by differences in clinical practice and case-finding activity. It is likely, however, that substantive geographical differences exist both in terms of genetic susceptibility and environmental factors that potentially trigger the disease in genetically susceptible individuals. The study of the epidemiology of PBC has strongly supported the concept of an environmental triggering factor, but as yet no specific agent has been identified. Ongoing work to discover the environmental agent, as well as the mechanism that causes the disease will answer key questions as to the epidemiology of this complex autoimmune disease as well as providing useful information for other autoimmune conditions.

Keywords

primary biliary cirrhosis - epidemiology

• References

• 1 Triger DR, Berg PA, Rodes J. Epidemiology of primary biliary cirrhosis. Liver 1984; 4 (3) 195-200
• 2 Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005; 25 (3) 298-310
• 3 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. AASLD. Primary Biliary Cirrhosis. Hepatology 2009; 50 (1) 291-230
• 4 Oertelt S, Rieger R, Selmi C , et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007; 45 (3) 659-665
• 5 Kingham JG, Parker DR. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 1998; 42 (1) 120-122
• 6 James OFW, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV. Primary biliary cirrhosis once rare, now common in the United Kingdom?. Hepatology 1999; 30 (2) 390-394
• 7 Metcalf JV, Bhopal RS, Gray J, Howel D, James OF. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int J Epidemiol 1997; 26 (4) 830-836
• 8 Rautiainen H, Salomaa V, Niemelå S , et al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol 2007; 42 (11) 1347-1353
• 9 Danielsson A, Boqvist L, Uddenfeldt P. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology 1990; 11 (3) 458-464
• 10 Löfgren J, Järnerot G, Danielsson D, Hemdal I. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand J Gastroenterol 1985; 20 (5) 647-650
• 11 Kim WR, Lindor KD, Locke III GR , et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119 (6) 1631-1636
• 12 Farrell GC. Primary biliary cirrhosis in Asians: less common than in Europeans, but just as depressing. J Gastroenterol Hepatol 2008; 23 (4) 508-511
• 13 Metcalf J, James O. The geoepidemiology of primary biliary cirrhosis. Semin Liver Dis 1997; 17 (1) 13-22
• 14 Robson SC, Hift RJ, Kirsch RE. Primary biliary cirrhosis. A retrospective survey at Groote Schuur Hospital, Cape Town. S Afr Med J 1990; 78 (1) 19-22
• 15 Invernizzi P. Geoepidemiology of autoimmune liver diseases. J Autoimmun 2010; 34 (3) J300-J306
• 16 Su CW, Hung HH, Huo TI , et al. Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. Liver Int 2008; 28 (9) 1305-1313
• 17 Inoue K, Hirohara J, Nakano T , et al. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 1995; 15 (2) 70-77
• 18 Mori MTA, Kojima M , et al. Nationwide survey of intractable hepatic disorders in Japan. In: Welfare MoHa, , ed. Annual Report of Research Committee on Epidemiology of Intractable Diseases. Nagoya, Japan: Research Committee on Epidemiology of Intractable Diseases; 1997
• 19 Liu H, Liu Y, Wang L , et al. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol 2010; 10: 100
• 20 Watson RG, Angus PW, Dewar M, Goss B, Sewell RB, Smallwood RA. Melbourne Liver Group. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Gut 1995; 36 (6) 927-930
• 21 Sood S, Gow PJ, Christie JM, Angus PW. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology 2004; 127 (2) 470-475
• 22 Myers RP, Shaheen AA, Fong A , et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology 2009; 50 (6) 1884-1892
• 23 Witt-Sullivan H, Heathcote J, Cauch K , et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990; 12 (1) 98-105
• 24 Sherlock S. Primary billiary cirrhosis (chronic intrahepatic obstructive jaundice). Gastroenterology 1959; 37: 574-586
• 25 Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973; 289 (13) 674-678
• 26 Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996; 348 (9039) 1399-1402
• 27 Prince MI, Chetwynd A, Diggle P, Jarner M, Metcalf JV, James OF. The geographical distribution of primary biliary cirrhosis in a well-defined cohort. Hepatology 2001; 34 (6) 1083-1088
• 28 McNally RJ, Ducker S, James OF. Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis. Hepatology 2009; 50 (4) 1169-1174
• 29 Ala A, Stanca CM, Bu-Ghanim M , et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006; 43 (3) 525-531
• 30 Triger DR. Primary biliary cirrhosis: an epidemiological study. BMJ 1980; 281 (6243) 772-775
• 31 Gershwin ME, Selmi C, Worman HJ , et al; USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42 (5) 1194-1202
• 32 Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OF. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology 2000; 31 (5) 1055-1060
• 33 Prince MI, Ducker SJ, James OFW. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 2010; 59 (4) 508-512
• 34 Carbone M, Mells GF, Pells G , et al; UK PBC Consortium. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144 (3) 560-569 , e7, quiz e13–e14
• 35 Pells G, Mells GF, Carbone M , et al; UK-PBC Consortium. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. J Hepatol 2013; 59 (1) 67-73
• 36 Mells GF, Pells G, Newton JL , et al; UK-PBC Consortium. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 2013; 58 (1) 273-283
• 37 Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130 (3) 715-720
• 38 Corpechot C, Abenavoli L, Rabahi N , et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48 (3) 871-877
• 39 Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55 (6) 1361-1367
• 40 Alvaro D, Invernizzi P, Onori P , et al. Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol 2004; 41 (6) 905-912
• 41 Reddy A, Prince M, James OFW, Jain S, Bassendine MF. Tamoxifen: a novel treatment for primary biliary cirrhosis?. Liver Int 2004; 24 (3) 194-197
• 42 Jones DEJ, Sutcliffe K, Pairman J, Wilton K, Newton JL. An integrated care pathway improves quality of life in Primary Biliary Cirrhosis. QJM 2008; 101 (7) 535-543
• 43 Mason A, Luketic V, Lindor K , et al. Farnesoid-X receptor agonists: a new class of drug for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol 2010; 52: S1-S2
• 44 Newton JL, Pairman J, Sutcliffe K, Wilton K, Jones DEJ. A predictive model for fatigue and its etiologic associations in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2008; 6 (2) 228-233
• 45 Hirschfield GM, Liu X, Xu C , et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360 (24) 2544-2555
• 46 Mells GF, Floyd JAB, Morley KI , et al; UK PBC Consortium; Wellcome Trust Case Control Consortium 3. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011; 43 (4) 329-332
• 47 Liu JZ, Almarri MA, Gaffney DJ , et al. Dense fine-mapping study identifies novel disease loci and implicates coding and non-coding variation in primary biliary cirrhosis risk. Nat Genet 2012; 44: 1137-1141
• 48 Hirschfield GM, Liu X, Han Y , et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 2010; 42 (8) 655-657
• 49 Jones DEJ, Mells G. The genetics of primary biliary cirrhosis: the revolution moves on. Hepatology 2011; 53 (1) 362-364
• 50 Walden HR, Kirby JA, Yeaman SJ, Gray J, Jones DE, Palmer JM. Xenobiotic incorporation into pyruvate dehydrogenase complex can occur via the exogenous lipoylation pathway. Hepatology 2008; 48 (6) 1874-1884
• 51 Yeaman SJ, Kirby JA, Jones DEJ. Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis. Immunol Rev 2000; 174: 238-249
• 52 Long SA, Quan C, Van de Water J , et al. The aetiology of primary biliary cirrhosis: connecting xenobiotics to anti-mitochondrial antibodies by ab initio quantum chemistry. Hepatology 2001; 34: 341A
• 53 Long SA, Quan C, Van de Water J , et al. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol 2001; 167 (5) 2956-2963
• 54 Leung PS, Quan C, Park O , et al. Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol 2003; 170 (10) 5326-5332
• 55 Leung PSC, Park O, Tsuneyama K , et al. Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol 2007; 179 (4) 2651-2657